1-2 of 2
Annalisa Chiarenza
Close
Sort by
Journal Articles

Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study

Alberto Fresa, Francesco Autore, Alfonso Piciocchi, Gioacchino Catania, Andrea Visentin, Annamaria Tomasso, Marina Moretti, Candida Vitale, Annalisa Chiarenza, Francesca Morelli, Paolo Sportoletti, Roberto Marasca, Giuseppe Sapienza, Annarosa Cuccaro, Roberta Murru, Alessandro Sanna, Caterina Patti, Ilaria Angeletti, Marta Coscia, Livio Trentin, Daniela Pietrasanta, Idanna Innocenti, Luca Laurenti
Journal: Blood Advances
Blood Adv (2022) 6 (13): 3875–3878.
https://doi.org/10.1182/bloodadvances.2022006964
Published: 2022
Includes: Supplemental data
Journal Articles

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

Clinical Trials & Observations
Alessandra Tedeschi, Anna Maria Frustaci, Francesca Romana Mauro, Annalisa Chiarenza, Marta Coscia, Stefania Ciolli, Gianluigi Reda, Luca Laurenti, Marzia Varettoni, Roberta Murru, Claudia Baratè, Paolo Sportoletti, Antonino Greco, Chiara Borella, Valentina Rossi, Marina Deodato, Annalisa Biagi, Giulia Zamprogna, Angelo Curto Pelle, Gianfranco Lapietra, Candida Vitale, Francesca Morelli, Ramona Cassin, Alberto Fresa, Chiara Cavalloni, Massimiliano Postorino, Claudia Ielo, Roberto Cairoli, Francesco Di Raimondo, Marco Montillo, Giovanni Del Poeta
Journal: Blood Advances
Blood Adv (2021) 5 (24): 5490–5500.
https://doi.org/10.1182/bloodadvances.2021004824
Published: 2021
Includes: Supplemental data